These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome. Moerman RV; Arends S; Meiners PM; Vissink A; Spijkervet FK; Kroese FG; Brouwer E; Bootsma H J Rheumatol; 2017 Mar; 44(3):292-296. PubMed ID: 28089983 [TBL] [Abstract][Full Text] [Related]
29. Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). van Nimwegen JF; Mossel E; van Zuiden GS; Wijnsma RF; Delli K; Stel AJ; van der Vegt B; Haacke EA; Olie L; Los LI; Verstappen GM; Pringle SA; Spijkervet FKL; Kroese FGM; Vissink A; Arends S; Bootsma H Lancet Rheumatol; 2020 Mar; 2(3):e153-e163. PubMed ID: 38263653 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome. Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813 [TBL] [Abstract][Full Text] [Related]
31. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity. Mandl T; Marsal J; Olsson P; Ohlsson B; Andréasson K Arthritis Res Ther; 2017 Oct; 19(1):237. PubMed ID: 29065905 [TBL] [Abstract][Full Text] [Related]
32. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome. Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296 [TBL] [Abstract][Full Text] [Related]
34. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome. Brown S; Navarro Coy N; Pitzalis C; Emery P; Pavitt S; Gray J; Hulme C; Hall F; Busch R; Smith P; Dawson L; Bombardieri M; Wan-Fai N; Pease C; Price E; Sutcliffe N; Woods C; Ruddock S; Everett C; Reynolds C; Skinner E; Poveda-Gallego A; Rout J; Macleod I; Rauz S; Bowman S; BMC Musculoskelet Disord; 2014 Jan; 15():21. PubMed ID: 24438039 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009 [TBL] [Abstract][Full Text] [Related]
36. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial. Shao Q; Wang S; Jiang H; Liu L Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847 [No Abstract] [Full Text] [Related]
38. Ten years of the ESSDAI: is it fit for purpose? de Wolff L; Arends S; van Nimwegen JF; Bootsma H Clin Exp Rheumatol; 2020; 38 Suppl 126(4):283-290. PubMed ID: 33095151 [TBL] [Abstract][Full Text] [Related]
39. Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting. Pavlych V; Di Muzio C; Alunno A; Carubbi F Front Med (Lausanne); 2020; 7():534. PubMed ID: 33015092 [No Abstract] [Full Text] [Related]
40. Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. Seror R; Baron G; Camus M; Cornec D; Perrodeau E; Bowman SJ; Bombardieri M; Bootsma H; Gottenberg JE; Fisher B; Hueber W; van Roon JA; Devauchelle-Pensec V; Gergely P; Mariette X; Porcher R; ; Ann Rheum Dis; 2022 Jul; 81(7):979-989. PubMed ID: 35393271 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]